menu
    • menu
    [{"orgOrder":0,"company":"CellCentric","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Inobrodib","moa":"p300\/CBP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CellCentric \/ Morningside Venture","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Morningside Venture"},{"orgOrder":0,"company":"CellCentric","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Inobrodib","moa":"||EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CellCentric \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Pfizer Inc"},{"orgOrder":0,"company":"CellCentric","sponsor":"BrightEdge","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Inobrodib","moa":"EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CellCentric \/ BrightEdge","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ BrightEdge"},{"orgOrder":0,"company":"CellCentric","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inobrodib","moa":"||EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CellCentric \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CellCentric

    Menu

    CellCentric

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inobrodib,Dexamethasone

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Pfizer Inc

    Deal Size : $25.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    CellCentric Announces $25m Strategic Investment from Pfizer

    Details : The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.

    Product Name : CCS1477

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 07, 2023

    Lead Product(s) : Inobrodib,Dexamethasone

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Pfizer Inc

    Deal Size : $25.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inobrodib,Dexamethasone

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CellCentric To Present Inobrodib Phase I Multiple Myeloma Efficacy And Safety Data At The American Society Of ...

    Details : Inobrodib (CCS1477) is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers, to treat late stage multiple myeloma patients.

    Product Name : CCS1477

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 11, 2022

    Lead Product(s) : Inobrodib,Dexamethasone

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inobrodib

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : BrightEdge

    Deal Size : Undisclosed

    Deal Type : Funding

    DEALS_DEV arrow-down

    CellCentric Secures Investment from The American Cancer Society’s Impact Venture Capital Fund

    Details : The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Inve...

    Product Name : CCS1477

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 26, 2022

    Lead Product(s) : Inobrodib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : BrightEdge

    Deal Size : Undisclosed

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed

    CellCentric

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Inobrodib

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Morningside Venture

    Deal Size : $33.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    CellCentric Raises $33m to Broaden Clinical Trials of its First-in-Class p300/CBP Inhibitor, CCS1477

    Details : CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with p300/CBP mutations. CellCentric plans to investigate CCS1477 both as a monotherapy and in combination with stan...

    Product Name : CCS1477

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 22, 2020

    Lead Product(s) : Inobrodib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Morningside Venture

    Deal Size : $33.0 million

    Deal Type : Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth